MedWatch

MSD shocked over medicines council: "We have a system that doesn't work"

Pharmaceutical company MSD is puzzled by the Danish Medicines Council's choice to temporarily halt its reassessment of the firm's cancer remedy Keytruda in a specific lung indication after a meeting on Wednesday, even though it's now been two years since the European Medicines Agency approved the drug.

The Danish Medicines Council's choice to postpone its decision on approving MSD's cancer remedy prompts criticism. | Foto: MSD / PR

Pharmaceutical company MSD once again has to prepare for a waiting period prior to knowing whether the Danish Medicines Council will approve its big seller, cancer remedy Keytruda (pembrolizumab) targeting a particular type of lung cancer.

Quite unexpectedly, the council elected during its latest meeting on Wednesday to put the remedy, which would benefit at least 300 patients a year, on temporary hold, so-called extended clock-stop.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier